Abstract
Recent investigations suggested a mild defect in cell-mediated immunity in patients with psoriasis vulgaris [1]. It is not dear, however, whether these findings are of pathogenetic importance or solely represent epiphenomena of a chronic inflammatory disorder. Transfer factor therapy can restore cellular immunity in certain pathological conditions [2]. Thus, a clinical pilot study of this preparation seemed justified in psoriasis. Transfer-Faktor human (polyvalent), Fa. Schura Blutderivate, Krefeld, FRG, was used in this study (we thank Dr. Baginski for providing the preparation). It consists of deoxyribonuclease-treated, dialyzed lysates of pooled leucocytes from at least 10,000 human blood donors in a lyophilized form. The reconstituted solution represents 5 • 10 l~ leucocytes/100 ml. Dosage: Day 1: I ml/kg body weight. Day 4: 2 ml/kg. Day 8 : 3 ml/kg intravenously. Four patients were included in this pilot study:
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
